Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission

Psychopharmacology

Volumn 232, Issue 3, 2015, Pages 605-621

  Snyder, Gretchen L ^a   Vanover, Kimberly E ^a   Zhu, Hongwen ^a   Miller, Diane B ^b   O'Callaghan, James P ^b   Tomesch, John ^a   Li, Peng ^a   Zhang, Qiang ^a   Krishnan, Vaishnav ^c,e   Hendrick, Joseph P ^a   Nestler, Eric J ^c   Davis, Robert E ^d   Wennogle, Lawrence P ^a   Mates, Sharon ^a  

^a Intra Cellular Therapies Inc   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d 3 D Pharmaceutical Consultants Inc   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Dopamine D2< inf> receptor; Mesocortical; Microdialysis; Nigrostriatal; NMDA receptors; Nucleus accumbens; Schizophrenia; Serotonin 5 HT2A< inf> receptor; Serotonin transporter; Social defeat

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; SEROTONIN 2 ANTAGONIST;

ANIMAL; ANIMAL BEHAVIOR; BRAIN; C57BL MOUSE; DRUG DEVELOPMENT; DRUG EFFECTS; MALE; METABOLISM; MOUSE; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG DISCOVERY; GLUTAMIC ACID; MALE; MICE; MICE, INBRED C57BL; NEUROTRANSMITTER AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84937734124     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3704-1     Document Type: Article

References (66)

1. Alimohamad H, Rajakumar N, Seah YH, Rushlow W (2005) Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 57:533-42
2. Ancoli-Israel S, Vanover KE, Weiner DM, Davis RE, van Kammen DP (2011) Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med 12:134-141
3. Auclair A, Drouin C, Cotecchia S, Glowinski J, Tassin J-P (2004) 5-HT2A and α1b-adrenergic receptors entirely mediate dopamine release, locomotor response, and behavioral sensitization to opiates and psychostimulants. Eur J Neurosci 20:3073-3084
4. Beaulieu J-M, Gainetdinov RR, Caron MG (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49:327-347
5. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, Graham D, Tsankova NM, Bolanos CA, Rios M, Monteggeia DW, Nestler EJ (2006) Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311:864-8
6. Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM (1997) RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 36:621-9
7. Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH, Marquis KL (2010) WS-50030 [7-[4-[3-(3-(1H-inden-3-yl)propyl]piperazin-1-yl)-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin uptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity. J Pharmacol Exp Ther 332:190-210
8. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca R, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-9
9. Carty NC, Xu J, Kurup P, Brouillette J, Goebel-Goody SM, Austin DR, Yuan P, Chen G, Correa PR, Haroutunian V, Pittenger C, Lombroso PJ (2012) The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Transl Psychiatr. doi: 10.1038/tp.2012.63
10. Chaudhury D, Walsh JJ, Friedman AK, Juarez B, Ku SM, Koo JW, Ferguson D, Tsai HC, Pomeranz L, Christoffel DJ, Nectow AR, Ekstrand M, Domingos A, Mazei-Robison MS, Mouzon E, Lobo MK, Neve RL, Friedman JM, Russo SJ, Deisseroth K, Nestler EJ, Han MH (2013) Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature 493:532-536
11. Clark D, Hjorth S, Carlsson A (1984) (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis. Eur J Pharmacol 106:185-9
12. Conn PJ, Sanders-Bush E (1984) Selective 5-HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology 23:993-996
13. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
14. Davis K, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatr 148:1474-1486
15. Factor SA, Friedman JH (1997) The emerging role of clozapine in the treatment of movement disorders. Mov Disord 12:483-496
16. Field JR, Walker AG, Conn PJ (2012) Targeting glutamate synapses in schizophrenia. Trends Mol Med 17:689-698
17. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75-81
18. Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, Veinbergs I, Dyssegaard A, Brunmark P, Tabatabaei A, Davis RE, Brann MR, Hacksell U, Bonhaus DW (2007) ACP-103, a 5-hydroxytriptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J Pharmacol Exp Ther 322:862-870
19. Goebel-Goody SM, Davies KD, Alvestad Linger RM, Freund RK, Browning MD (2009) Phospho-regulation of synaptic and extrasynaptic N-methyl-D-aspartate receptors in adult hippocampal slices. Neuroscience 158:1446-59
20. Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, Gémesi L, Pásztor G, Zájer-Balázs KM, Csongor EA, Domány G, Tihanyi K, Szombathelyi Z (2011) Cariprazine (RGH-188), a potent D3/D2 dopamine receptor agonist, binds to dopamine D2 receptors in vivo and shows antipsychotic-like and precognitive effects in rodents. Neurochem Int 59:925-35
21. Harada K, Wu J, Haycock JW, Goldstein M (1996) regulation of L-DOPA biosynthesis by site-specific phosphorylation of tyrosine hydroxylase in At-20 cells expressing wild-type and serine 40-substituted enzyme. J Neurochem 64:629-635
22. Harvey ML, Swallows CL, Cooper MA (2012) A double dissociation in the effects of 5-HT2A and 5-HT2C receptors on the acquisition and expression of conditioned defeat in Syrian hamsters. Behav Neurosci 126:530-537
23. Hattori K, Uchino S, Isosaka T, Maekawa M, Iyo M, Sato T, Kohsaka S, Yagi T, Yuasa S (2006) Fyn is required for haloperidol-induced catalepsy in mice. J Biol Chem 281:7129-7139
24. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001) 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531
25. Ichikawa J, Li Z, Dai J, Meltzer HY (2002) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 956:349-357
26. Jardemark K, Marcus MM, Shahid M, Svensson TH (2010) Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: Involvement of dopamine D1 receptors. Synapse 64:870-874
27. Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors and dopamine-glutamate interactions. Int Rev Neurobiol 78:69-108
28. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatr 45:789-796
29. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatr 63:763-71
30. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, CATIE Investigators; Neurocognitive Working Group (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiat 64:633-647
31. Krishnan V, Nestler EJ (2011) Animal models of depression: molecular perspectives. Curr Top Behav Neurosci 7:121-47
32. Kroeze WK, Hufelsen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) Hi-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-26
33. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatr 51:199-214
34. Laruelle M, Frankle G, Narendran R, Kegeles LS, Abi-Dargham A (2005) Mechanism of action of antipsychotic drugs: from dopamine D2 receptor antagonism to glutamate NMDA facilitation. Clin Ther 2:S16-S24
35. Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA (2007) Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol 10:7-19
36. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223
37. Marek GJ, Martin-Ruiz R, Abo A, Artigas F (2005) The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 30:2205-2215
38. Matsui-Sakata A, Ohtani H, Sawada Y (2005) Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 20:368-378
39. Meltzer HY, Fatemi SH (1996) The role of serotonin in schizophrenia and the mechanism of action of antipsychotic drugs. In: Kane JM, Moller HJ, Awouters F (eds) In Serotonin in antipsychotic treatment: mechanisms and clinical practice. Marcel Dekker, New York, pp 77-107
40. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-46
41. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from the prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755-1760
42. Moghaddam B, Javitt D (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacol Rev 37:4-15
43. Morairty SR, Hedley L, Flores J, Martin R, Kilduff TS (2008) Selective 5-HT2A and 5-HT6 receptor antagonists promote sleep in rats. Sleep 31:34-44
44. Nakai S, Hirose T, Uwahodo Y, Imaoka T, Okazaki H, Miwa T, Nakai M, Yamada S, Dunn B, Burris KD, Molinoff PB, Tottori K, Altar CA, Kikuchi T (2003) Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur J Pharmacol 472:89-97
45. Nakazawa T, Komai S, Tezuka T, Hisatsune C, Umemori H, Semba K, Mishina M, Manabe T, Yamamoto T (2001) Characterization of fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J Biol Chem 276:693-699
46. Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiat 13:27-35
47. Ohno Y, Ishida K, Ikeda K, Ishibashi T, Okada K, Nakamura M (1994) Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test. Pharmacol Biochem Behav 49:19-23
48. Owens JM, Morgan WN, Plott SJ, Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305-22
49. Owens JM, Knight DL, Nemeroff CB (2002) Second generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Encéphale 28:350-5
50. Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J (1996) Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacol (Berl) 126:234-40
51. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA, Investigators CAFÉ (2009) Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFÉ study. Schizophr Res 111:9-16
52. Popa D, Lena C, Fabre V, Prenat C, Gingrich J, Escourrou P, Hamon M, Adrien J (2005) Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control and functional adaptations in knock-out mice lacking 5-HT2A receptors. J Neurosci 25:11231-11238
53. Porter RHP, Benwell KR, Lam H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ (1999) Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B, and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol 128:13-20
54. Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther 125:169-179
55. Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev 3:353-9
56. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-41
57. Rygula R, Abumaria N, Havemann-Reinecke U, Rüther E, Hiemke C, Zernig G, Fuchs E, Flügge G (2008) Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam. Behav Pharmacol 19:183-196
58. Sánchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467-89
59. Schwartz TL, Sachdeva S, Stahl SM (2012) Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol 3:195
60. Stoof JC, Kebabian JW (1981) Opposing roles for D-1 and D-2 dopamine receptors in the efflux of cyclic AMP from rat neostriatum. Nature 294:366-8
61. Sutherland C, Cohen P (1994) The alpha-isoform of glycogen synthase kinase-3 from rabbit skeletal muscle is inactivated by p70 S6 kinase or MAP kinase-activated protein kinase-1 in vitro. FEBS Lett 338:37-42
62. Svensson K, Eriksson E, Carlsson A (1993) Partial dopamine receptor agonists reverse behavioral, biochemical, and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects. Neuropharmacology 32:1037-45
63. Tamminga CA, Buchanan RW, Gold JM (1998) The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 13(Suppl 3):S21-6
64. Vanover KE, Davis RE (2010) Role of 5-HT2A antagonists in the treatment of insomnia. Nat Sci Sleep 2:139-150
65. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S (2001) Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25:633-41
66. Zhu H, O'Brien JJ, O'Callaghan JP, Miller DB, Zhang Q, Rana M, Tsui T, Peng Y, Tomesch J, Hendrick JP, Wennogle LP, Snyder GL (2010) Nerve agent exposure elicits site-specific changes in protein phosphorylation in mouse brain. Brain Res 1342:11-23